GenVec
 | |
| Public company | |
| Traded as | NASDAQ: GNVC |
| Industry | Pharmaceuticals |
| Headquarters | Gaithersburg, Maryland, United States |
Key people |
Douglas J. Swirsky, President and CEO |
| Products | CGF166Clinical trial#Phase 1/2 |
 | |
| Website | www.genvec.com |
GenVec, Inc. (NASDAQ: GNVC) is a pioneering biopharmaceutical company working to build a pipeline of therapeutics and vaccines based on its adenovector technology platform that can realize the promise of gene-based medicine. The company's lead product candidate for hearing loss and balance disorders, partnered with Novartis, is in a first-in-man gene delivery Phase 1/2 clinical trial in patients with severe to profound hearing loss. GenVec therapeutics and vaccines have been administered to over 3,000 clinical study subjects.